Immune Checkpoint Inhibitors

• 

  Subject Areas on Research

  • A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. 
  • A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer. 
  • A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. 
  • A multicenter characterization of hepatitis associated with immune checkpoint inhibitors. 
  • ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS/STING activation. 
  • Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. 
  • Advanced Melanoma: Resistance Mechanisms to Current Therapies. 
  • Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. 
  • Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer. 
  • Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma. 
  • Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer. 
  • CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation. 
  • Cancer-cell-derived GABA promotes β-catenin-mediated tumour growth and immunosuppression. 
  • Cardiometabolic Consequences of Targeted Anticancer Therapies. 
  • Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma. 
  • Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook. 
  • Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper From the Fleischner Society. 
  • Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study. 
  • Clinicoserological insights into patients with immune checkpoint inhibitor-induced myasthenia gravis. 
  • Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. 
  • Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study. 
  • Combination of a novel heat shock protein 90-targeted photodynamic therapy with PD-1/PD-L1 blockade induces potent systemic antitumor efficacy and abscopal effect against breast cancers. 
  • Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity. 
  • Combination strategies to maximize the benefits of cancer immunotherapy. 
  • Comparative Efficacy of Treatments for Brain Metastases from Non-Small Cell Lung Cancer without an EGFR-Mutation/ALK-Rearrangement: A Systematic Review and Network Meta-Analysis. 
  • Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. 
  • Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study. 
  • Dissecting the Functional Significance of DNA Polymerase Mutations in Cancer. 
  • Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. 
  • Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. 
  • Effect of prior antibiotic or chemotherapy treatment on immunotherapy response in non-small cell lung cancer. 
  • Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial. 
  • Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma. 
  • Findings on Chest CT Performed in the Emergency Department in Patients Receiving Immune Checkpoint Inhibitor Therapy: Single-Institution 8-Year Experience in 136 Patients. 
  • Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. 
  • High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. 
  • Imaging and clinical manifestations of immune checkpoint inhibitor-related colitis in cancer patients treated with monotherapy or combination therapy. 
  • Immune Checkpoint Inhibitor-associated Uveitis: Review of Treatments and Outcomes. 
  • Immune Checkpoint Inhibitors Do Not Increase Short-Term Risk of Hypertension in Cancer Patients: a Systematic Literature Review and Meta-Analysis. 
  • Immune Checkpoint Inhibitors in the Aged. 
  • Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas. 
  • Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course. 
  • Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. 
  • Inhibition of ALG3 stimulates cancer cell immunogenic ferroptosis to potentiate immunotherapy. 
  • Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer. 
  • International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. 
  • Intratumoral Plasmid IL12 Expands CD8+ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti-PD-1 Therapy. 
  • LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types. 
  • MRI of tumor T cell infiltration in response to checkpoint inhibitor therapy. 
  • Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. 
  • Modulating the wayward T cell: New horizons with immune checkpoint inhibitor treatments in autoimmunity, transplant, and cancer. 
  • Myocarditis associated with immune checkpoint inhibitor therapy: a case report of three patients. 
  • New agents and regimens for diffuse large B cell lymphoma. 
  • PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma? 
  • Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non-small cell lung cancer. 
  • Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. 
  • Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. 
  • Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760). 
  • Post-irradiation intratumoral heterogeneity modulates response to immune checkpoint inhibition therapy in a murine melanoma model. 
  • Posterior Uveitis Associated with Cemiplimab. 
  • Predictive Value of Combining Biomarkers for Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. 
  • Predictive factors of neoadjuvant immune checkpoint blockade in melanoma. 
  • Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. 
  • Relationship Between Progression-Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD-1/PD-L1 Immune Checkpoint Blockade: A Meta-Analysis. 
  • Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. 
  • Risk Factors for Immunotherapy-related Adverse Events (IrAE) in Patients Treated With Immune Checkpoint Inhibitors. 
  • SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition. 
  • Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study. 
  • Sensitizing immune unresponsive colorectal cancers to immune checkpoint inhibitors through MAVS overexpression. 
  • Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. 
  • Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer. 
  • Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy. 
  • Targeting Histone Deacetylase 6 Reprograms Interleukin-17-Producing Helper T Cell Pathogenicity and Facilitates Immunotherapies for Hepatocellular Carcinoma. 
  • The landscape of contemporary clinical trials for untreated metastatic clear cell renal cell carcinoma. 
  • Therapeutic plasma exchange in the management of immune checkpoint inhibitor-associated immune-related adverse effects: A review. 
  • Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. 
  • Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. 
  • Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer. 
  • Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay.